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Smoking remains the leading cause of preventable death in the
United States.1,2 Tobacco use increases the risk of multiple can-
cers, including lung, oropharyngeal, pancreas, bladder, stom-
ach, and colon.3 Continued tobacco use following a cancer di-
agnosis increases the risk of
cancer recurrence, new pri-
mary cancers, and adverse
treatment-related outcomes, including postoperative pulmo-
nary complications, poor surgical healing, and decreased re-
sponse to chemotherapeutic drugs.4
In contrast, tobacco cessation after cancer diagnosis is of-
ten associated with improved quality of life, fewer complica-
tions related to cancer treatment, and longer survival.4 In a
2018 study, the prevalence of cigarette smoking among adult
cancer survivors was 11.8%,5 and many cancer survivors who
quit smoking after a diagnosis may resume smoking.6 Failure
to address the unique challenges of cessation contributes to
lack of success in initial cancer treatment due to ongoing smok-
ing and has been associated with an estimated incremental cost
of nearly $11 000 per year per smoking patient.7
Tobacco abstinence is the strongest predictor of cancer sur-
vival, after cancer type and stage at the time of diagnosis.8
While guidelines from the National Comprehensive Cancer Net-
work recommend cessation counseling and pharmacologic
treatment for patients with cancer who are interested in quit-
ting smoking,4 a survey of 1153 physicians of the Interna-
tional Association for the Study of Lung Cancer found that only
44% reported treating their patients’ tobacco dependence.9
Barriers to cessation treatment in oncology include time con-
straints and lack of tobacco cessation training.10 A 2019 meta-
analysis of randomized clinical trials of tobacco cessation
among patients with cancer found no consistently effective in-
terventions, despite similar studies showing efficacy in the gen-
eral population.11
It is in this context that the study by Park et al12 in this is-
sue of JAMA provides an important contribution to the oncol-
ogy literature. In this unblinded study conducted at 2 Na-
tional Cancer Institute (NCI) Comprehensive Cancer Centers,
the authors randomly assigned 303 patients with newly diag-
nosed cancer who smoked cigarettes to an intensive treat-
ment group, with 4 weekly, 4 biweekly, and 3-monthly smok-
ing cessation telephone counseling sessions coupled with
12 weeks of free cessation medication (either nicotine replace-
ment therapy, bupropion, or varenicline) or to a standard treat-
ment group, with 4 weekly telephone counseling sessions and
medication advice, without provision of free medication. In-
tention-to-treat analysis of the 221 patients who completed the
study (78.1% completion rate) showed that patients in the in-
tensive treatment group achieved biochemically confirmed,
higher 7-day abstinence rates at 6-month follow-up (34.5%)
compared with patients in the standard treatment group
(21.5%). While the 13% absolute between-group difference
was slightly less than hypothesized, this difference may be
clinically meaningful.
This theory-driven research provides evidence that inten-
sive smoking counseling over at least 6 months contributes to
an effective approach to smoking cessation in patients with
cancer. Patients in the intensive counseling group completed
a median of 8 counseling sessions compared with a median of
4 sessions in the standard treatment group, and in multivar-
iate models, medications had little influence on effect size es-
timates. Approximately 30% of patients (22/74) who had quit
smoking at 3 months relapsed by 6 months, whereas 35% of
patients (28/80) still smoking at 3 months had quit by 6 months,
resulting in modest additional quitting gains (34.5% vs 31.1%)
at 6 months. The therapists who provided the counseling had
expert training in motivational interviewing, cognitive-
based therapy, stress reduction, and cancer-specific support.
The study by Park et al12 has a number of limitations, as
acknowledged by the authors. The study was conducted as a
randomized clinical trial, in which patients received free coun-
seling and medication, and they were rewarded financially for
study procedures (up to $200 for baseline, follow-up sur-
veys, and salivary/expired air specimens), which might have
served as an unintended incentive for overall participation or
abstinence, although this would be expected to be balanced
between treatment groups. It took the investigators almost 4
years to recruit the patients, and most of those screened for
eligibility declined participation, suggesting potential barri-
ers to broad uptake that warrant future implementation re-
search. Patients and clinicians were not blinded to treatment,
patients with lower literacy levels were mostly excluded, and
the study was conducted in only 2 cancer centers, limiting gen-
eralizability. In addition, the study did not measure cessation
rates beyond 6 months, and relapse, even after 6 months of
successful quitting, is not infrequent.6
The study was not designed to assess the potential ef-
fects of e-cigarette use despite its frequent use in the inten-
sive treatment group (17.7%) and the standard treatment group
(19.5%). e-Cigarette use has increased among cancer survi-
vors in the last decade. In a recent study of 1527 cancer survi-
vors, 3.8% used e-cigarettes, and 25% of cancer survivors with
complete information on product use (n = 159) reported dual
use of tobacco products.13 Interventions that assess and ad-
dress e-cigarette and dual use among patients with cancer
should be undertaken.
Identification of a dose-response relationship of counsel-
ing, alone or in combination with medication, would be
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on ways to expand the scope of intensive counseling that is in-
tegrated into routine cancer care processes. Because the cur-
rent study showed that greater numbers of counseling ses-
sions as well as booster sessions extending out to 6 months led
to a higher likelihood of quitting in the intensive group, thera-
pists in cancer programs should strive to achieve both met-
rics. Currently, in many centers, only a minority of patients re-
ferred for counseling receive such counseling,15,18,19 and
advanced cessation programs may struggle to provide 4 or more
patient counseling sessions.15
Payers and health system leaders must acknowledge that
current fee-for-service models for cancer treatment are incon-
gruent with models of sustainable intensive smoking cessa-
tion counseling. Reimbursement for Medicare, Medicaid, and
most private insurers only pays for 4 counseling sessions per
quit attempt.20 Reimbursement in the fee-for-service model
is based on evaluation and management physician billing codes
for treatment, rather than certified tobacco treatment special-
ists who provide intensive counseling and use low reimburse-
ment preventive counseling codes. Such codes do not incen-
tivize additional counseling, and they do not reimburse at levels
to sustain intensive programs. Given the cost-effectiveness of
smoking cessation for patients with cancer and the conse-
quences of failed treatment, value- and incentive-based reim-
bursements would potentially engender greater uptake of more
intensive counseling from trained cessation therapists. If pay-
ers are willing to reimburse cancer centers thousands of dol-
lars per patient annually for cancer treatments, they should
be willing to invest in intensive cessation coverage, which ul-
timately lowers cost and improves outcomes.
Implementing intensive cessation counseling requires
more than formulaic algorithms of treatment protocols. Sys-
tem-level change supported by patients, clinician groups, and
cancer centers must occur, with provision of resources from
payers and health care systems. In such an environment, cli-
nicians can call on the best evidence from well-designed stud-
ies and use the art of medicine: the connection and empathy
that foster patient trust and tailor treatments to each indi-
vidual, devoid of stigma and judgment.
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